OneSource Specialty Pharma LimitedQ1FY27 Results & Financial Update
OneSource Specialty Pharma Limited: Q1FY27 consolidated results and company financials – revenue ₹449.02 Cr, PAT ₹25.00 Cr. Explore reported YoY/QoQ movements, margins, business drivers and management commentary. This page does not provide a rating, target price or investment recommendation.
Quarter at a glanceReported figures and period changes.Changes compare like-for-like reported periods where available.
Find an answer
Ask this result
Chart · Market context
OneSource Specialty Pharma price & chart
Market price₹1,478.20
1Y return—Price return
Loading market chart…
TradingView Lightweight Charts™ · Copyright © 2025 TradingView, Inc.TradingView
Market chartPrice chart temporarily unavailableThe price chart could not be loaded right now. The reported financial results remain available above.
Spotted a factual error?Tell us the number, date or statement and we will re-check the underlying records and calculations.Report an error
Quarterly Results AnalysisExplore OneSource Specialty Pharma Q1FY27 quarterly results and earnings: revenue, profit (PAT), EBITDA, margins, YoY and QoQ growth, order book or business updates where reported, financial performance and management commentary. Reported figures and Nivata calculations are shown separately; no buy, sell or hold recommendation is provided.
Quarter overview
Quarterly earnings analysis
OneSource Specialty Pharma delivered a strong start to FY27, reporting consolidated revenue from operations of INR 449.023 crore for the quarter ended June 30, 2026, marking a significant increase compared to both previous quarters and the corresponding period of the previous year.
The top-line momentum was underpinned by the commercialization and scaling of semaglutide in Canada and India, new master service agreement (MSA) contracts, and customer wins across various dosage modalities.
Profitability metrics showed substantial improvement during the quarter, with consolidated profit after tax turning positive to INR 24.997 crore, supported by operating leverage on higher semaglutide revenues.
In the investor communication and press releases, management highlighted that company-adjusted EBITDA reached INR 1,233 million (up 39% year-on-year) with EBITDA margins expanding to 27.5%, bolstered by efficiency gains and operating leverage.
Operational milestones during Q1 FY27 included advancing the first phase of capacity expansion, preparing the second cartridge line for commercial operations in Q2, and securing key customer wins and strategic biosimilar partnerships.
The company maintained its robust compliance track record with ongoing regulatory inspections and audits, positioning itself favorably to capture upcoming global patent expiries.
01 · Business model
What does OneSource Specialty Pharma do?
OneSource Specialty Pharma Limited operates as a pure-play specialty pharmaceutical contract development and manufacturing organization (CDMO), providing development and manufacturing solutions across complex pharmaceutical products.
The company's core offerings span diverse high-barrier modalities including biologics, drug-device combinations (DDCs such as GLP-1 pens), sterile injectables, and soft gelatin capsules.
It maintains five state-of-the-art manufacturing facilities approved by global regulatory authorities, supported by a professional workforce of over 1,600 employees.
Serving a global customer base of more than 80 pharma companies, OneSource leverages integrated development and commercial scale capabilities across microbial and mammalian systems as well as drug-device assembly.
02 · Historical context
What shaped the business before this quarter
Previously known as Stelis Biopharma Limited, the company transitioned its corporate structure and brand to OneSource Specialty Pharma Limited to focus entirely on specialty CDMO operations.
The company grew its active RFP funnel from $28 million in February 2025 to over $101 million by July 2026, reflecting accelerating customer engagement.
03 · Financial snapshot
Current quarter vs the two useful baselines
| Metric | Q1FY27 | Year-ago | Previous quarter |
|---|---|---|---|
| Revenue from operations | ₹449.02 Cr | ₹327.27 Cr | ₹428.22 Cr |
| Total income | ₹452.83 Cr | ₹332.54 Cr | ₹430.31 Cr |
| Profit before tax | ₹20.29 Cr | ₹-4.40 Cr | ₹-0.29 Cr |
| Profit after tax | ₹25.00 Cr | ₹-0.19 Cr | ₹4.60 Cr |
| EPS | ₹2.18 | ₹-0.02 | ₹0.40 |
Financial interpretation
What the reported numbers mean
Profit after tax represented 5.6% of reported quarterly operating revenue. This is a calculated net-profit-to-sales ratio, not a company-reported operating margin. It measures the outcome after expenses and tax; it does not, by itself, establish how margins changed versus another period.
Profit before tax was equivalent to 4.5% of quarterly operating revenue. The distinction between pre-tax and post-tax profit matters when interpreting earnings; neither ratio identifies an underlying cost driver without a properly matched comparative period.
Total income exceeded operating revenue by ₹3.80 crore. This is the disclosed difference between the two lines, not incremental sales. The distinction matters when assessing how much of the quarter’s reported income came from the operating top line.
Ratios above are calculated from the reported quarterly figures. They are analytical descriptions, not company-reported margin guidance or an investment recommendation.
04 · Why it moved
Why the quarter looked the way it did
What drove revenue
Revenues were driven by the ongoing commercial launch and volume ramp-up of semaglutide across key off-patent markets including Canada and India.
Execution of new master service agreements and customer additions across various modalities contributed to sequential top-line expansion.
What drove margins
EBITDA margins expanded due to operating leverage generated from higher production volumes and revenue scaling in the semaglutide portfolio.
05 · Demand, customers & order book
Where demand is coming from
Added 6 new customer logos during the quarter, taking total customers to over 80, alongside 11 new wins and an active RFP pipeline exceeding $101 million.
06 · Segments, products & geography
Which parts of the business are doing the work
Segments and products
Maintained leadership in GLP-1 products, supplying multiple partners across 3 G7 semaglutide approvals and securing 2 First-to-File filings in tirzepatide.
Gathered further momentum with the addition of a marquee biosimilar customer (Formycon) and expansion across microbial (1 KL) and mammalian (4 KL) systems.
Geography and market mix
Achieved significant commercial traction with 3 out of 3 customer approvals launched in Canada and supplying 10 out of 21 generic pen brands in India.
Partnered with Hikma, one of the largest pharma players in the Middle East and North Africa, with product launches scheduled shortly.
07 · Capacity, projects & execution
What is being built, commissioned or delivered
Capacity, production and utilisation
Phase 1 capacity expansion neared completion, with the second cartridge line scheduled to enter commercial operations in Q2, doubling total sterile production days.
Projects, capex and execution
The company reported that 80% of its announced $100 million capex program is fully committed to fund ongoing facility and line expansions.
08 · Strategy & new businesses
How the company is trying to change its growth mix
Formed a strategic partnership with Formycon to combine integrated DS and DP capabilities with an independent developer pipeline for global biosimilar supply.
09 · Reported developments
What changed operationally
Maintained a strong compliance track record across five state-of-the-art facilities, successfully completing 12 regulatory inspections and customer audits.
10 · Items worth noticing
The line items that can distort a quick read
Consolidated financial results included an exceptional gain/adjustment of INR 43.00 million during the quarter.
11 · Management guidance & targets
What management is targeting from here
Management reaffirmed its FY28 guidance of achieving $400 million in organic revenue with a steady-state EBITDA margin of 40% and targeted ROCE exceeding 50%.
12 · Beyond the numbers
What changed beyond the numbers
Reported update
ESG Ratings
Achieved an NSE Sustainability Rating of 73/100 (Leader category) and an EcoVadis score of 64/100 (Bronze, Top 35%).
13 · Key Q&A
The quarter, answered directly
What does OneSource Specialty Pharma do?
OneSource Specialty Pharma Limited operates as a pure-play specialty pharmaceutical contract development and manufacturing organization (CDMO), providing development and manufacturing solutions across complex pharmaceutical products.
What is the clearest takeaway from Q1FY27?
OneSource Specialty Pharma delivered a strong start to FY27, reporting consolidated revenue from operations of INR 449.023 crore for the quarter ended June 30, 2026, marking a significant increase compared to both previous quarters and the corresponding period of the previous year.
What drove revenue or demand?
Revenues were driven by the ongoing commercial launch and volume ramp-up of semaglutide across key off-patent markets including Canada and India.
What mattered most for margins or profitability?
EBITDA margins expanded due to operating leverage generated from higher production volumes and revenue scaling in the semaglutide portfolio.
What changed operationally beyond the headline numbers?
Phase 1 capacity expansion neared completion, with the second cartridge line scheduled to enter commercial operations in Q2, doubling total sterile production days.
What is management guiding or targeting from here?
Management reaffirmed its FY28 guidance of achieving $400 million in organic revenue with a steady-state EBITDA margin of 40% and targeted ROCE exceeding 50%.
14 · Scenario calculator
Earnings sensitivity: what if growth and margins change?
Starting point
Build your own next-quarter scenario
Reported values are prefilled where a comparable basis is available. Otherwise, the field starts at 0. You can overwrite every field.
Example: enter 10 for 10% revenue growth. Enter -100 for a 1 percentage-point margin decline.
Scenario output
Scenario revenue / income₹0 cr
Scenario profit after tax₹0 cr
Profit change vs base₹0 cr (0%)
Scenario margin0%
Growth needed to keep profit flat after this margin move0%
The calculator holds the selected margin basis constant except for the basis-point adjustment you enter. It does not estimate tax, finance cost, dilution, working capital, valuation or share price.
15 · Next filing checkpoints
What the next disclosure can confirm or change
- 01
Q2 Commercialization: Monitor the successful commercial operation commencement of the second cartridge line during Q2 FY27.
Learn the metrics
Need the concepts first?
Use Nivata’s plain-English guides to understand the accounting terms used in this brief before interpreting them.